Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06545929 · ClinicalTrials.gov registry record · Phase 2
Study of Sunobinop on Craving in Alcohol Use Disorder
A Phase 2 study of Alcohol Use Disorder, sponsored by Imbrium Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06545929 is a Phase 2 study of Alcohol Use Disorder that has completed, run by Imbrium Therapeutics. The registered enrollment target is 40 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06545929, a Phase 2 study of Alcohol Use Disorder, has completed, sponsored by Imbrium Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol craving in subjects with moderate to severe alcohol use disorder and these subjects are seeking treatment.
Conditions Studied
Interventions
- DRUG Sunobinop
- DRUG Placebo to match sunobinop
Study Locations (1)
Ohio
- Ohio Clinical Trials - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-01-28 |
| Est. Completion | 2025-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06545929
The ClinicalTrials.gov registry entry for NCT06545929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (88% lower). The listed sponsor is Imbrium Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Sunobinop is the first listed.
NCT06545929 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06545929 about?
NCT06545929 is a clinical study titled "Study of Sunobinop on Craving in Alcohol Use Disorder". The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol craving in subjects with moderate to severe alcohol use disorder and these subjects are seeking treatment.
What is the current status of trial NCT06545929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-01-28. Estimated completion is 2025-07-14.
What conditions does trial NCT06545929 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT06545929?
The interventions under investigation include: Sunobinop (DRUG), Placebo to match sunobinop (DRUG).
Who is sponsoring clinical trial NCT06545929?
This trial is sponsored by Imbrium Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06545929 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.